EMJ Hematology 9 [Supplement 3] . 2021

In this issue

In this supplement to EMJ Hematology, two leading haematologists, Prof Adriano Venditti and Prof Lars Bullinger, discussed the management of patients with acute myeloid leukaemia (AML) and fms-related tyrosine kinase 3 (FLT3) gene mutations. Specifically, the roles for emerging treatment options and maintenance strategies in improving outcomes for patients with a FLT3 internal tandem duplication (ITD) mutation were explored.

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.